# AIRWAY THERAPEUTICS, INC.: A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care.

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | AIRWAY THERAPEUTICS, INC. |
| Location | Atlanta, GA |
| Project | A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care. |
| Project number | 1R44HL186892-01 |
| Mechanism | R44 |
| Institute | National Heart Lung and Blood Institute |
| Award | $1,906,253 |
| Awarded | 2026-09-10 |
| Project period | 2026-09-10 to 2027-06-30 |
| UEI | KXA4TU327G25 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11407847). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.